{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T05:55:33Z","timestamp":1790229333161,"version":"4.1.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.revmed.2016.01.012","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T12:48:54Z","timestamp":1455886134000},"page":"551-560","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Tumeurs neuroendocrines digestives"],"prefix":"10.1016","volume":"37","author":[{"given":"L.","family":"de Mestier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Deguelte-Lardi\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Brixi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Kianmanesh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Cadiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2016.01.012_bib0240","first-page":"160","article-title":"Epidemiology of digestive neuroendocrine tumors with focus on French data","volume":"20","author":"Walter","year":"2013","journal-title":"Hepato-Gastro"},{"key":"10.1016\/j.revmed.2016.01.012_bib0245","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1530\/ERC-12-0024","article-title":"Neuroendocrine tumor disease\u00a0\u2013\u00a0an evolving landscape","volume":"19","author":"Frilling","year":"2012","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0250","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S1470-2045(13)70362-0","article-title":"Recommendations for management of patients with neuroendocrine liver metastases","volume":"15","author":"Frilling","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.revmed.2016.01.012_bib0255","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825\u00a0cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J Clin Oncol"},{"issue":"S7","key":"10.1016\/j.revmed.2016.01.012_bib0260","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1002\/cncr.23648","article-title":"Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies","volume":"113","author":"Jensen","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0265","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.annpat.2014.01.003","article-title":"Gastroenteropancreatic neuroendocrine tumors: what must the pathologist know and do in 2014?","volume":"34","author":"Scoazec","year":"2014","journal-title":"Ann Pathol"},{"key":"10.1016\/j.revmed.2016.01.012_bib0270","series-title":"WHO classification of tumours of the digestive system","first-page":"13","article-title":"Nomenclature and classification of neuroendocrine neoplasms of the digestive system","author":"Rindi","year":"2010"},{"key":"10.1016\/j.revmed.2016.01.012_bib0275","doi-asserted-by":"crossref","first-page":"2814","DOI":"10.1002\/cncr.28721","article-title":"Gastroenteropancreatic high-grade neuroendocrine carcinoma","volume":"120","author":"Sorbye","year":"2014","journal-title":"Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0280","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3\u00a0gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0285","series-title":"TNM classification of malignant tumours","first-page":"310","author":"Sobin","year":"2010"},{"key":"10.1016\/j.revmed.2016.01.012_bib0290","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1007\/s00428-006-0250-1","article-title":"TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system","volume":"449","author":"Rindi","year":"2006","journal-title":"Virchows Arch"},{"key":"10.1016\/j.revmed.2016.01.012_bib0295","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1007\/s00428-007-0452-1","article-title":"TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system","volume":"451","author":"Rindi","year":"2007","journal-title":"Virchows Arch"},{"key":"10.1016\/j.revmed.2016.01.012_bib0300","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1097\/SLA.0b013e31828f3174","article-title":"A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine Tumors: a validation of current staging systems and a new prognostic nomogram","volume":"259","author":"Ellison","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.revmed.2016.01.012_bib0305","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000335591","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes","volume":"95","author":"Jensen","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0310","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ecl.2010.12.001","article-title":"The clinical relevance of chromogranin a as a biomarker for gastroenteropancreatic neuroendocrine tumors","volume":"40","author":"Lawrence","year":"2011","journal-title":"Endocrinol Metab Clin North Am"},{"key":"10.1016\/j.revmed.2016.01.012_bib0315","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.bpg.2012.12.002","article-title":"Neuroendocrine tumours of the small intestine","volume":"26","author":"Strosberg","year":"2012","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.revmed.2016.01.012_bib0320","unstructured":"Soci\u00e9t\u00e9 nationale fran\u00e7aise de gastroent\u00e9rologie. Th\u00e9saurus national de canc\u00e9rologie digestive. http:\/\/www.tncd.org [Acc\u00e8s au site le 8\u00a0novembre 2015]."},{"key":"10.1016\/j.revmed.2016.01.012_bib0325","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1200\/JCO.2007.12.7431","article-title":"Indium-111-pentetreotide scintigraphy and somatostatin receptor subtype 2\u00a0expression: new prognostic factors for malignant well-differentiated endocrine tumors","volume":"26","author":"Asnacios","year":"2008","journal-title":"J Clin Oncol"},{"issue":"Suppl.\u00a01","key":"10.1016\/j.revmed.2016.01.012_bib0330","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1007\/s00259-011-1989-4","article-title":"68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET","volume":"39","author":"Ambrosini","year":"2012","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"10.1016\/j.revmed.2016.01.012_bib0335","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1210\/jc.2010-2022","article-title":"Performance of (18)fluorodeoxyglucose-positron emission tomography and somatostatin receptor scintigraphy for high Ki67 (\u226510\u00a0%) well-differentiated endocrine carcinoma staging","volume":"96","author":"Abgral","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2016.01.012_bib0340","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1210\/jc.2008-1349","article-title":"Impact of fluorodihydroxyphenylalanine-18F positron emission tomography on management of adult patients with documented or occult digestive endocrine tumors","volume":"94","author":"Montravers","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.revmed.2016.01.012_bib0345","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1159\/000371817","article-title":"Updating the surgical management of peritoneal carcinomatosis in patients with neuroendocrine tumors","volume":"101","author":"de Mestier","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0350","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000287255","article-title":"ENETS consensus guidelines for the management of bone and lung metastases from neuroendocrine tumors","volume":"91","author":"Kos-Kud\u0142a","year":"2010","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0355","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1677\/ERC-09-0319","article-title":"Ki-67\u00a0index, tumor differentiation, and extent of liver involvement are independent prognostic factors in patients with liver metastases of digestive endocrine carcinomas","volume":"18","author":"Hentic","year":"2011","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0360","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1677\/ERC-08-0017","article-title":"Prognostic factors of long-term outcome in gastroenteropancreatic neuroendocrine tumours","volume":"15","author":"Pape","year":"2008","journal-title":"Endocr Relat Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0365","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1093\/jnci\/djs208","article-title":"TNM staging of neoplasms of the endocrine pancreas: results from a large international cohort study","volume":"104","author":"Rindi","year":"2012","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.revmed.2016.01.012_bib0370","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1159\/000335597","article-title":"ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary","volume":"95","author":"Pavel","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0375","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1159\/000335595","article-title":"ENETS Consensus Guidelines for the management of patients with gastroduodenal neoplasms","volume":"95","author":"Delle Fave","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0380","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000335587","article-title":"ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms of the digestive system: well-differentiated pancreatic non-functioning tumors","volume":"95","author":"Falconi","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0385","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1097\/SLA.0000000000000856","article-title":"Long-term prognosis of resected pancreatic neuroendocrine tumors in von Hippel-Lindau disease is favorable and not influenced by small tumors left in place","volume":"262","author":"de Mestier","year":"2015","journal-title":"Ann Surg"},{"key":"10.1016\/j.revmed.2016.01.012_bib0390","article-title":"Toward preoperative classification of lymph-node metastases in patients with small intestine neuroendocrine tumours in the era of intestinal-sparing surgery","author":"Lardi\u00e8re-Deguelte","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0395","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1159\/000335629","article-title":"ENETS Consensus Guidelines for the management of patients with neuroendocrine neoplasms from the jejuno-ileum and the appendix including goblet cell carcinomas","volume":"95","author":"Pape","year":"2012","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0400","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1055\/s-0033-1344794","article-title":"Updating the management of patients with rectal neuroendocrine tumors","volume":"45","author":"de Mestier","year":"2013","journal-title":"Endoscopy"},{"key":"10.1016\/j.revmed.2016.01.012_bib0405","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/hpb.12308","article-title":"Liver transplantation for neuroendocrine tumour liver metastases","volume":"17","author":"Fan","year":"2015","journal-title":"HPB"},{"key":"10.1016\/j.revmed.2016.01.012_bib0410","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.dld.2011.08.022","article-title":"New treatment strategies in advanced neuroendocrine tumours","volume":"44","author":"Walter","year":"2012","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.revmed.2016.01.012_bib0415","doi-asserted-by":"crossref","first-page":"4656","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide lar in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group","volume":"27","author":"Rinke","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.revmed.2016.01.012_bib0420","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1056\/NEJMoa1316158","article-title":"Lanreotide in metastatic enteropancreatic neuroendocrine tumors","volume":"371","author":"Caplin","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.01.012_bib0425","first-page":"835","article-title":"Antiproliferative effect of somatostatin analogs in neuroendocrine tumors","volume":"21","author":"de Mestier","year":"2014","journal-title":"Hepato-Gastro"},{"key":"10.1016\/j.revmed.2016.01.012_bib0430","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1159\/000430816","article-title":"Temozolomide in advanced neuroendocrine neoplasms: pharmacological and clinical aspects","volume":"101","author":"Koumarianou","year":"2015","journal-title":"Neuroendocrinology"},{"key":"10.1016\/j.revmed.2016.01.012_bib0435","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s11523-012-0219-8","article-title":"Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract","volume":"7","author":"Zappa","year":"2012","journal-title":"Target Oncol"},{"key":"10.1016\/j.revmed.2016.01.012_bib0440","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib Mmlate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.01.012_bib0445","doi-asserted-by":"crossref","first-page":"3107","DOI":"10.1016\/j.ejca.2014.10.001","article-title":"Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)\u00a0\u2013\u00a0A phase II non-randomised trial","volume":"50","author":"Mitry","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0450","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1016\/j.ejca.2014.10.002","article-title":"Bevacizumab combined with 5-FU\/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial)\u00a0\u2013\u00a0A phase II non-randomised trial","volume":"50","author":"Ducreux","year":"2014","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0455","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.revmed.2016.01.012_bib0470","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(15)00817-X","article-title":"Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study","author":"Yao","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2016.01.012_bib0465","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1186\/s12885-015-1512-6","article-title":"Evaluation of the efficacy and safety of lanreotide in combination with targeted therapies in patients with neuroendocrine tumours in clinical practice: a retrospective cross-sectional analysis","volume":"15","author":"Capdevila","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.revmed.2016.01.012_bib0235","series-title":"Present\u00e9 \u00e0 l\u2019European Cancer Congress 2015","article-title":"177-Lu-Dotatate significantly improves progression-free survival in patients with midgut neuroendocrine tumours: results of the phase III NETTER-1\u00a0trial (abstract LBA-6)","author":"Strosberg","year":"2015"}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316000436?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866316000436?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:36:28Z","timestamp":1759336588000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866316000436"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":47,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0248866316000436"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2016.01.012","relation":{},"ISSN":["0248-8663"],"issn-type":[{"value":"0248-8663","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tumeurs neuroendocrines digestives","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2016.01.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Soci\u00e9t\u00e9 Nationale Fran\u00e7aise de M\u00e9decine Interne (SNFMI). Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}